In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
Robert A. Huddart, MB, PhD, BS
Advertisement
Articles by Robert A. Huddart, MB, PhD, BS
Advertisement
Latest Updated Articles
Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer PatientsPublished: November 8th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
2
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
3
Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
